| Judgment Phase | Common Misconceptions | Recommended Practices |
|---|---|---|
Classification Confirmation | Adopt identical registration route merely based on similar appearance | Complete classification definition, standard sorting and application scope confirmation beforehand |
Clinical Evaluation | Predicate route is available as long as imported counterparts exist on market | Finish discrepancy-risk-evidence mapping prior to deciding on clinical trial requirement |
QMS Preparation | Compile documents intensively shortly before sample testing or submission | Carry out R&D, verification, sterilization & packaging and QMS construction in parallel |
Under current regulatory requirements, failures during embolization coil registration rarely stem from lack of mature reference products but habitual empirical copying adopted by most developers. For high-risk implantable devices, inappropriate route determination will lead to mismatched investment in raw material control, laboratory tests and quality system construction.
Manufacturers commonly mistake similar product appearance for identical registration pathways when developing embolization coils. In fact, intended use, implantation site, working mechanism, coating configuration, biodegradable material adoption and matched dedicated delivery system all affect classification outcomes and review focus.
Regulatory requirements differ greatly between intracranial and peripheral indications, bare coils and functionalized variants, as well as conventional and innovative registration applications, making universal templates inapplicable. According to the Technical Guidelines for Clinical Evaluation of Medical Devices, applicants shall prepare evaluation documents matching product characteristics to verify safety and effectiveness. Meanwhile, the Special Review Procedure for Innovative Medical Devices mandates pre-submission assessment on innovation, intellectual property and clinical value prior to initial Class II and Class III registration.
Instead of assuming rapid registration due to mature product category, enterprises shall recognize embolization coils as high-risk implantable devices whose registration route and supporting evidence shall be customized per intended use, structure and technical features. Early-stage correct orientation outweighs simplistic feasibility judgment for sponsors.
In accordance with the Technical Guidelines for Clinical Evaluation of Medical Devices issued by NMPA in 2021, clinical evaluation is not a binary procedural task but a systematic demonstration focusing on product safety, effectiveness as well as benefit-risk profile. For high-risk implantable interventional devices, manufacturers commonly underestimate that eligibility for the predicate-based pathway does not hinge on commercially available imported products, but on whether discrepancies between the investigational product and predicate device can be scientifically and fully justified and verified.
For embolization coil projects, such challenges mainly manifest in three aspects. First of all, indications cannot be generalized. Applications for intracranial aneurysms, arteriovenous fistulas, arteriovenous malformations and peripheral vascular lesions shall not be bundled indiscriminately at the initial stage. Secondly, core technical features require in-depth comparison instead of superficial checks. Detachment mechanism, embolization principle, dimensional specification system, delivery compatibility and radiopacity all govern equivalence assessment results. Thirdly, full supporting evidence shall be provided for all divergent items. Alterations in raw materials, coating, expansion properties or other critical performances cannot justify clinical trial exemption merely by analogous clinical application experience.
This section addresses clients' core concern: whether clinical trials are mandatory for embolization coil registration. Instead of a simplistic yes-or-no reply, the professional answer is that clinical trial requirement is determined by the feasibility of predicate equivalence demonstration and whether all variances can be fully verified via non-clinical tests and existing clinical data.
A common misconception for embolization coil development is deferring material and quality system preparation until shortly before testing submission. As implantable devices contacting blood circulation and remaining indwelling in human body for long-term periods, such products are reviewed not only based on final test data but also the consistency, traceability and rationality behind all test records.
NMPA mandates biological evaluation in compliance with GB/T 16886 series standards, and relevant animal study guidelines specify that animal tests cannot replace biological assessment. Any biocompatibility verification via animal experiments shall also comply with GB/T 16886 and relevant technical specifications.
Accordingly, manufacturers cannot solely rely on raw material certificates but need to validate safety and stability of finished products. Key basic items dominating review efficiency of embolization coils include traceable raw material batches, controlled critical process parameters, compatibility verification between coils and delivery systems, verifiable full data records for sterilization and packaging, and biological evaluation covering all risk items corresponding to product-body contact modes.
It is noteworthy that NMPA issued the revised Good Manufacturing Practice for Medical Devices in November 2025, which shall come into force on November 1, 2026. Enterprises planning registration submission in 2026 shall complete advance improvement on design control, verification and validation, change management, document traceability and supplier management from now on.
Conclusion: Embolization coils are feasible for registration but incompatible with low-threshold development mindset. Manufacturers planning product layout are advised to prioritize three early-stage preparatory tasks.
| Key Actions | Key Recommendations |
|---|---|
Conduct Registration Route Analysis Upfront | Complete classification confirmation, sorting of applicable standards and determination of submission route based on product intended use, application site, raw materials and technical features, to avoid direction deviation discovered at mid-to-late R&D stage. |
Perform Discrepancy Analysis First | Do not directly interpret "marketed existing products" as "eligible for clinical trial exemption". Instead, establish the corresponding relationship between predicate devices, discrepancy items, risk points and evidence strategy beforehand. |
Advance R&D and QMS Construction in Parallel | For implantable and interventional devices, material consistency, biocompatibility evaluation, sterilization and packaging validation, design and development records, and supply chain traceability shall be established synchronously during project implementation. |
For embolization coils, a seemingly mature yet high-threshold product category, project efficiency hinges not on existing precedents, but on manufacturers' capability to convert proven experience into compliant supporting evidence.
With increasingly refined regulatory rules, updated product guidance documents and intensified domestic substitution competition, proficiency in classification confirmation, predicate-based clinical evaluation, QMS consultation, biocompatibility assessment and registration evidence compilation has become the decisive factor for project success or failure.
To avoid detours at the project initiation stage, enterprises shall prioritize systematic registration strategy planning for implantable interventional devices instead of simply adopting ready-made templates. This embodies the core value of professional medical device CROs: interpreting practical implications of regulatory requirements, specifying immediate actions, and efficiently transforming R&D outcomes into reviewable, inspectable and market-accessible evidence packages.
Professional Insight from Deda Medical
For ongoing registration assessment of embolization coils or intracranial/peripheral implantable interventional devices, early-stage classification confirmation, clinical evaluation route analysis and quality system preparation are recommended to mitigate extra costs and timeline delays caused by late supplementary tests and scheme revisions. Customized registration consultation and access to the Catalogue of Medical Device Classification are available upon team contact.
This article is compiled based on official published NMPA regulatory documents for reference only. Final registration plans shall be formulated in accordance with specific product features and latest regulatory provisions, and adequate regulatory communication is suggested at critical project milestones.
• List of Current Technical Review Guidelines for Medical Device Registration (as of Feb 2026)
• NMPA Announcement on Issuing the Good Manufacturing Practice for Medical Devices
• Delivery Information of Approved Medical Device Certificates (Mar 03, 2026)
• Delivery Information of Approved Medical Device Certificates (Apr 07, 2026)
